Atara生物治療 ATRA 深 滬
等待開盤 03-26 09:30:00 美东时间
4.96
-0.030
-0.60%
華盛通- 最 高5.35
- 今 開5.07
- 成交量 6.61万股
- 最 低 4.95
- 昨 收 4.99
- 總市值 3576.28万
- 52周最高 19.145
- 市盈率 靜 1.93
- 換手率 0.92%
- 52周最低 3.92
- 委 比 75.35%
- 總股本 721.02万
- 歷史最高 1639.00
- 量 比 0.74
- 振 幅 8.02%
- 歷史最低 3.92
- 每 手 1
- 風險率 4.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Atara Plans FDA Type A Meeting on EBVALLO
The latest update is out from Atara Biotherapeutics ( ($ATRA) ). On March 12, 2...
03-12 20:37
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Mesoblast Limited announced the appointment of Dr. Teresa Montagut as Head of Clinical Development and Medical Affairs, tasked with advancing the company's cell therapy programs for pediatric and adult inflammatory conditions. Dr. Montagut brings extensive experience in medical leadership and cancer immunotherapy development, previously leading programs at Regeneron, Novartis, and Genentech. Mesoblast is focused on developing allogeneic cellular ...
03-11 23:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Relmada Therapeutics (NASDAQ:RLMD) stock rose 48.3% to $6.6 during Mon...
03-09 20:05
Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Submits Request To FDA For Type A Meeting About ALLELE Trial
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
03-03 21:27
BRIEF-Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
BRIEF-Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel March 3 (Reuters) - Atara Biotherapeutics Inc ATRA.O : ATARA BIOTHERAPEUTICS PROVIDES REGULATORY UPDATE ON TABELECLEUCEL Source text: ID:nBwcf5zT8a Further company coverage: ATRA.O (( Reuters.Briefs@thomsonreuters.com ;))
03-03 21:12
Atara jumps amid report on FDA’s U-turn on cell therapy
Shares of Atara Biotherapeutics (ATRA) climbed on Wednesday after Stat News reported that the U.S. FDA rejected the company’s cell therapy tabelecleucel last month despite its internal reviewers recom...
02-26 02:56
Atara Biotherapeutics Extends $9 Million HCRx Milestone Payment Due Date to 2028
Atara Biotherapeutics Extends $9 Million HCRx Milestone Payment Due Date to 2028 Atara Biotherapeutics, Inc. said it entered into an amendment to its December 20, 2022 Purchase and Sale Agreement with a fund managed by HealthCare Royalty (HCRx). Under the amendment, HCRx agreed to extend the due dat
02-23 21:01
Atara's Outlook As Ebvallo Hits Second FDA CRL
Manufacturing Fixed, But Trial Interpretability Now Blocks US Approval Drug &am...
01-15 02:28
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6
Canaccord Genuity analyst John Newman downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Hold and lowers the price target from $25 to $6.
01-14 04:17
